Retroviral vectors for human gene delivery

Biotechnology Advances

Volumn 20, Issue 1, 2002, Pages 1-31

  McTaggart, Sally ^a   Al Rubeai, Mohamed ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cell culture; Gene delivery; Packaging cells; Retrovirus; Vector production; Viral vectors

Indexed keywords

CELL CULTURE; CELLS; DISEASES; MEDICAL APPLICATIONS;

VIRAL VECTORS;

GENETIC ENGINEERING;

BIOTECHNOLOGY; DISEASE CONTROL;

UNIDENTIFIED RETROVIRUS;

EID: 0036235391     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0734-9750(01)00087-8     Document Type: Article

References (127)

1. Industrial mammalian cell culture
2. Two-dimensional versus three-dimensional culture systems: Effects on growth and productivity of BHK cells
3. Coupled effects of Polybrene and calf serum on the efficiency of retroviral transduction and the stability of retroviral vectors
4. Moloney Murine Leukaemia Virus derived retroviral vectors decay intra-cellularly with a half-life in the range 5.5-7.5 hours
5. Cell cycle dependence of retroviral transduction: An issue of overlapping timescales
6. Large-scale processing of recombinant retroviruses for gene therapy
7. Effect of internal viral sequences on the utility of retroviral vectors
8. Gene therapy for cancer
9. Prospects for insulin delivery by ex-vivo somatic cell gene therapy
10. Adenovirus vectors for gene delivery
11. Production of retrovirus type-1 and type-3 from Vero cells grown on solid and macroporous microcarriers
12. T-lymphocyte directed gene therapy for ADA-SCID. Initial trial results after 4 years
13. Strategies for the isolation and purification of retroviral vectors for human gene therapy
14. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer
15. Vessicular Stomatitis Virus G glycoprotein pseudotyped retrovival vectors. Concentration to a very high Titreand efficient gene transfer into mammalian and nonmammalian cells
16. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells
17. Adeno-retroviral chimeric viruses as in vivo transducing agents
18. High density cultivation of recombinant CD-1 cell line producing prourokinase using a Biosilon microcarrier culture system
19. High density cultivation of genetically-engineered CHO cell lines with microcarrier culture systems
20. Electroporation for the efficient transfection of mammalian cells with DNA
21. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in non-myeloablated immunodeficient mice
22. The effects of hexadimethrine bromide (Polybrene) on the infection of the primate retroviruses SSV1/SSAV1 and BaEV
23. The end of the beginning
24. Regulated expression of a complete human β-globin gene encoded by a transmissible retrovirus vector
25. High-titre packaging cells producing recombinant retroviruses resistant to human serum
26. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type gene expression
27. Poxviruses as genetic vectors
28. Microcarrier culture: Applications in biologicals production and cell biology
29. Modelling retrovirus production for gene therapy: 1. Determination of optimal bioreaction mode and harvest strategy
30. Modelling retrovirus production for gene therapy: 2. Integrated optimisation of bioreaction and downstream processing
31. Innovative approaches to gene therapy
32. Current progress in the gene therapy of cancer
33. Functional characterisation of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
34. Viral vectors for gene therapy
35. Gene expression in mice after high efficiency retroviral-mediated gene transfer
36. Differences among nonhuman primates in susceptibility to bone marrow progenitor transduction with retrovirus vectors
37. Gene therapy for the haemophilias
38. Construction and characterisation of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase
39. Lentiviruses as gene delivery vectors
40. Retroviral end-point titre is not predictive of gene transfer efficiency: Implications for vector production
41. Gene therapeutics and gene therapy for cancer
42. Improved titres of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium
43. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18
44. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells
45. Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium
46. Gene therapy using retroviral vectors
47. VDEPT-Virus directed enzyme pro-drug therapy
48. Maximisation of perfusion systems and process comparison with batch-type cultures
49. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
50. PH control options for hybridoma cultures
51. Large-scale mammalian cell culture
52. Animal cell bioreactors - Recent advances and challenges to scale-up
53. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection
54. Some myths and messages concerning the batch and continuous culture of animal cells
55. Justification of continuous packed-bed reactor for retroviral vector production from amphotropic CRIP murine producer cell
56. Optimised conditions for the production of recombinant amphotropic retroviral vector preparations
57. Membrane anchored protein production from spheroid, porous, and solid microcarrier Chinese hamster ovary cell cultures
58. Production of high titre retroviral vectors and detection of replication-competent retroviruses
59. Bystander macrophages silence transgene expression driven by the retroviral long terminal repeat
60. A controlled study of the adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
61. Expression vectors and delivery systems. Tools for determining gene function and therapy
62. Improved methods of retroviral vector transduction and production for gene therapy
63. Retroviral vectors
64. Removal of proteoglycans increases efficiency of retroviral gene transfer
65. Kinetics of retrovirus production and decay
66. Optimization of environmental factors for the production and handling of recombinant retrovirus
67. Passage through mitosis is required for oncoretrovirus but not for human immunodeficiency virus
68. Immobilization of animal cells in porous carrier culture
69. Mechanisms of DNA entry into mammalian cells: II. Phagocytosis of calcium phosphate DNA coprecipitate visualized by electron microscopy
70. Biochemical recovery and purification of gene therapy vectors
71. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
72. Improved retroviral packaging lines derived from spleen necrosis virus
73. Human serum-resistant retroviral vector particles from galactosyl (α1-3) galactosyl containing nonprimate cell lines
74. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line
75. Relationship between cell proliferation, cell-cycle phase and retroviral vector production in FLYRD18 human packaging cells
76. Comparison of different bioreactor systems for the production of high titer retroviral vectors
77. Retrovirus packaging cells
78. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production
79. Improved retroviral vectors for gene transfer and expression
80. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
81. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
82. Delivering therapeutic genes - Matching approach and application
83. Ex vivo gene therapy in heart transplants
84. Retroviral vectors in human gene therapy
85. Retrovirus infection: Effect of time and target ell number
86. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
87. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: Evidence of direct viral binding to chymotryptic carboxy-terminal fragments
88. Lentiviruses as gene transfer agents for delivery to non-dividing cells
89. Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma
90. Comparative morphology and structural classification of retroviruses
91. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA
92. High density cultivation of hybridoma on charged porous carriers
93. Engineering challenges in high cell density culture systems
94. Activation of Moloney murine leukemia virus LTR enhances the titer of recombinant retrovirus in ψ CRIP packaging cells
95. The physico-chemical factors that govern retrovirus-mediated gene transfer
96. In pursuit of new developments for gene therapy of human diseases
97. Closed hollow-fiber bioreactor: A new approach to retroviral vector production
98. Therapeutic delivery issues in gene therapy: Part 1. Vectors
99. Cell engineering for muscle gene therapy: Extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes
100. Viral vector targeting
101. Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: A functional analysis of the role of TM domains in viral entry
102. A novel amphotropic packaging cell line: High titer, complement resistance and improved safety
103. Viral vectors for gene therapy
104. Integration of murine leukaemia virus (DNA) depends on mitosis
105. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes
106. Effect of temperature on recombinant protein expression in Semliki Forest virus infected mammalian cell lines grown in serum-free suspension cultures
107. Alphavirus vectors for gene expression and vaccines
108. Hybridoma growth, metabolism, and product formation in HEPES-buffered medium: II. Effect of pH
109. Immobilized cells: A review of recent literature
110. Retroviral preparations derived from PA317 packaging cells contain inhibitors which co-purify with viral particles and are devoid of viral vector RNA
111. Kinetics of retroviral production from the amphotropic ψ CRIP murine producer cell line
112. A transient three-plasmid expression system for the production of high titre retroviral vectors
113. Infection efficiency of T-lymphocytes with amphotropic retroviral vectors is cell cycle dependent
114. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell
115. Sensitization of cells and retroviruses to human serum by (alpha-1-3) galactosyltransferase
116. HIV protease as a target for retrovirus vector-mediated gene therapy
117. Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions
118. Gene therapy using adenoviral vectors
119. Improvement of retroviral re-targeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU
120. Scope and limitations of gene therapy
121. Continuous IgG production by myeloma cells immobilized within porous support particles
122. Immobilisation of anchorage-independent animal cells using reticulated polyvinyl formal resin biomass support particles
123. High efficiency retroviral vectors that contain no viral coding sequences